LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System

LENSAR, Inc.

FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.
ALLY is first FDA-cleared platform for femtosecond-laser cataract surgery in a single sterile environment.
Initial controlled launch planned for Q3 2022; wider availability targeted in 2023.
Over 125 surgeons experienced ALLY during live demonstrations at ASRS and company office.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.